DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BILCARE LTD. (BI) share price today?

BILCARE LTD. (BI) is trading at ₹61.3 on the NSE, down 2.73% on the day. Source: DocStoX.

What is the PE ratio of BILCARE LTD.?

BILCARE LTD. has a price-to-earnings (PE) ratio of 84.0 in the Healthcare sector.

What is the market capitalisation of BILCARE LTD.?

BILCARE LTD. has a market capitalisation of approximately ₹144 crore.

BILCARE LTD.

BI·NSE·Healthcare

₹61.30▼ -1.72 (-2.73%)

Healthcare · Healthcare Services

Revenue under pressure recently

Day₹61.30

₹63.50

52W₹52

₹7541%

Open

₹63.50

High

₹63.50

Low

₹61.30

Prev Close

₹63.02

Volume

1.1K

VWAP

₹62.07

Snapshot

Key fundamentals

Market Cap

₹144 Cr

P/E Ratio

83.97Expensive

P/B Ratio

0.73

EPS

₹0.73

Book Value

₹83.60

ROE

1.66%Weak

ROCE

6.00%Weak

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹10.00

52W High

₹75.00

52W Low

₹51.62

Sector

Healthcare

Industry

Healthcare Services

Expensive

None moatHigh uncertainty

Fair value estimate

₹64

▲ 5.0%upside

Trading at ₹61 — 5% below our estimate

BearFair valueBull

₹37₹64₹74

/100

Business quality — Watch the fundamentals

Growth 0Profitability 0Efficiency 0Valuation 0

Plain English

Our view

Revenue under pressure recently
Weak returns on equity (2%)

Risks

Weak returns on equity (2%)
Revenue has been shrinking
Expensive — trades at 84× earnings
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

2% ROE fading to 13% over ~3 yrs, on ₹84 book

₹72

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹37

Analyst target

No analyst coverage

—

Blended fair value₹64

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

Weak returns on equity (2%)
Revenue has been shrinking
Expensive — trades at 84× earnings
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

84.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

1.7%Weak

Above 15% is considered healthy for Indian equities

ROCE

6.0%Weak

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

₹144 Cr

P/B

0.73

EPS

₹0.73

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 84.0×

Growth

Shrinking

-9% rev CAGR

Profitability

Modest

1.7% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %72.3%

Turnover₹66,104 Cr

Trades39

VWAP₹62.07

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-9.3%

+3.3%

10Y

-11.9%

Profit

—

10Y

—

EPS

-51.5%

—

10Y

—

Profile

Pros

Stock is trading at 0.75 times its book value

Watch-outs

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 3.33% over past five years.
Promoter holding is low: 30.0%
Company has a low return on equity of -4.07% over last 3 years.
Contingent liabilities of Rs.727 Cr.
Earnings include an other income of Rs.26.2 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

30%

Promoter

Promoters

30.0%0.00

Public

70.0%0.00

FII / FPI

0.0%0.00

Total shareholders

15,824

Quarterly trend

Ownership over time

Q4 FY26

Promoter30.01%

FII0.04%

Public69.95%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).

BILCARE LTD. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

BILCARE LTD. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare BILCARE LTD. with peers

BILCARE LTD. vs SUN PHARMACEUTICAL IND L BILCARE LTD. vs DIVI S LABORATORIES LTD BILCARE LTD. vs TORRENT PHARMACEUTICALS L BILCARE LTD. vs APOLLO HOSPITALS ENTER. L BILCARE LTD. vs ZYDUS LIFESCIENCES LTD BILCARE LTD. vs CIPLA LTD

BILCARE LTD.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

BILCARE LTD. valuation & research

BILCARE LTD. peers in Healthcare

Compare BILCARE LTD. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions